Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03657550 · ClinicalTrials.gov registry record · Phase 1

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

A Phase 1 study, sponsored by Conjupro Biotherapeutics.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target

NCT03657550 is a Phase 1 study that has completed, run by Conjupro Biotherapeutics. The registered enrollment target is 36 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03657550, a Phase 1 study, has completed, sponsored by Conjupro Biotherapeutics.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target

Study Summary

This study are (1) to assess the relative bioavailability (BA) of a single oral dose of either 5 mg of Levamlodipine Maleate Tablets from CSPC or 10 mg of Amlodipine Besylate Tablet (NORVASC®) from Pfizer Inc. under fasting condition in male and female healthy subjects; and (2) to evaluate food effect on the PK profile of Levamlodipine Maleate Tablets from CSPC.

Interventions

  • DRUG Levamlodipine, Amlodipine
  • DRUG Amlodipine, Levamlodipine

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2018-05-31
Est. Completion 2018-09-06
Phase Phase 1

Sponsor

Conjupro Biotherapeutics

6 total trials

What the Registry Record Tells You About NCT03657550

The ClinicalTrials.gov registry entry for NCT03657550 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Conjupro Biotherapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Levamlodipine, Amlodipine is the first listed.

NCT03657550 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03657550 about?

NCT03657550 is a clinical study titled "Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects". This study are (1) to assess the relative bioavailability (BA) of a single oral dose of either 5 mg of Levamlodipine Maleate Tablets from CSPC or 10 mg of Amlodipine Besylate Tablet (NORVASC®) from Pfizer Inc. under fasting condition in male and female healthy subjects; and (2) to evaluate food effe...

What is the current status of trial NCT03657550?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-05-31. Estimated completion is 2018-09-06.

What interventions are being tested in trial NCT03657550?

The interventions under investigation include: Levamlodipine, Amlodipine (DRUG), Amlodipine, Levamlodipine (DRUG).

Who is sponsoring clinical trial NCT03657550?

This trial is sponsored by Conjupro Biotherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.